Component: (Network and Table)
Network
00400 - Statement - Consolidated Statements of Cash Flows
(http://www.enteromedics.com/role/StatementConsolidatedStatementsOfCashFlows)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Reporting Entity [Axis]0001371217 (http://www.sec.gov/CIK)
Consolidated Statements of Cash FlowsPeriod [Axis]
2016-01-01 - 2016-12-31
2015-01-01 - 2015-12-31
2014-01-01 - 2014-12-31
Consolidated Statements of Cash Flows
 
 
 
Cash flows from operating activities:
 
 
 
Net loss
(23,360,844) 
(25,498,747) 
(26,128,720) 
Adjustments to reconcile net loss to net cash used in operating activities:
 
 
 
Depreciation and amortization
139,576  
188,606  
188,904  
Provision for doubtful accounts
20,000  
  
Loss on sale of equipment
 
885  
 
Stock-based compensation
2,330,937  
6,939,777  
6,319,707  
Amortization of commitment fees, debt issuance costs and original issue discount
1,836,340  
825,735  
123,068  
Change in value of warrant liability
(3,512,816) 
(3,295,536) 
 
Change in operating assets and liabilities:
 
 
 
Accounts receivable
(105,625) 
(55,116) 
14,930  
Inventory
(103,254) 
(705,805) 
147,422  
Prepaid expenses and other current assets
354,732  
(409,822) 
125,071  
Other assets
(600,634) 
349,709  
(74,372) 
Accounts payable
1,139,656  
(222,636) 
267,356  
Accrued expenses
(891,060) 
(235,351) 
(355,294) 
Accrued interest payable
2,097,199  
(487,739) 
(11,735) 
Net cash used in operating activities
(20,655,793) 
 
(22,606,040) 
 
(19,383,663) 
 
Cash flows from investing activities:
 
 
 
Purchases of property and equipment
(14,000) 
(38,915) 
(88,680) 
Net cash used in investing activities
(14,000) 
 
(38,915) 
 
(88,680) 
 
Cash flows from financing activities:
 
 
 
Proceeds from warrants exercised
5,000  
 
2,242,265  
Proceeds from sale of common stock and warrants for purchase of common stock
 
22,651,932  
9,836,464  
Common stock financing costs
(28,000) 
(1,721,794) 
(284,698) 
Proceeds from convertible notes payable
17,250,000  
1,500,000  
 
Repayments on convertible notes payable
(446,867) 
  
Repayments on notes payable
 
(3,000,000) 
(4,000,000) 
Debt issuance costs
(726,793) 
(477,110) 
 
Net cash provided by financing activities
16,053,340  
 
18,953,028  
 
7,794,031  
 
Net (decrease) increase in cash and cash equivalents
(4,616,453) 
 
(3,691,927) 
 
(11,678,312) 
 
Cash and cash equivalents:
 
 
 
Beginning of period
7,927,240  
11,619,167  
23,297,479  
End of period
3,310,787  
 
7,927,240  
 
11,619,167  
 
Supplemental disclosure:
 
 
 
Cash paid for interest
155,407  
601,185  
418,889  
Noncash investing and financing activities:
 
 
 
Conversion of convertible notes and interest payable
20,318,024  
109,504